is a commercial-stage company and the recognized technology leader in minimally invasive medical devices that unite one console (XENIOS) with next-generation lung and heart therapies into a single platform for a market with revenue potential of nearly $9 billion.

XENIOS is the first to offer synchronized cardiac assist, which provides cardiac support in harmony with each heartbeat, designed to unite myocardial protection with organ perfusion.
Sept. 23, 2015— XENIOS Receives Cash Infusion from Existing Investors to Expand Commercial Operations in US and Europe.


XENIOS is the first to offer a complete product family of state-of-the-art solutions for minimally invasive treatment of acute and chronic lung failure without mechanical ventilation and without the need for patient sedation and mobilization.
heart failure
Lung failure

Xenios AG     Zukunftspark 1    Heilbronn, Germany 74076   +49 7131 2706 100 Legal NoticeEvents

The information contained on this site is intended for an audience outside the United States.